Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00894231

Enrollment

Registered

2009-05-06

Start date

2009-01-31

Completion date

2009-08-31

Last updated

2009-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perennial Allergic Rhinitis

Brief summary

The purpose of this study is to noninvasively measure the anti-inflammatory effect of levocetirizine after two weeks of treatment in allergic rhinitis subjects.

Interventions

DRUGlevocetirizine (Xyzal)

5mg po QD

DRUGplacebo

sugar tablet

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

12 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* ICF signed * Diagnosis of PAR for 6-12 months greater * 12 years and older * Decreased nasal NO values at baseline * Compliance and ability to perform maneuvers and responsibilities

Exclusion criteria

* Oral or systemic steroids for 60 days prior * Inhaled, nasal, nebulized steroids w/i 4 weeks * Hospitalization or life threatening asthma * Use of nasal or oral antihistamines w/i 4 weeks * Upper or lower airways infection * Direct cigarette smoke exposure

Design outcomes

Primary

Measure	Time frame
The change in objective measure of inflammation nasal NO after LC treatment.	two weeks

Secondary

Measure	Time frame
The change in nasal eosinophils, QOL and diary scores after LC treatment.	two weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026